Physicians in an environmental clinic in southern California conducted a study to determine the prevalence of autoantibodies in patients exposed to molds, mycotoxins, and other toxins
Vivarelli, F., Canistro, D., Cirillo, S., Papi, A., Spisni, E., Vornoli, A., Croce, C.M.D., Longo, V., Franchi, P., Filippi, S., Lucarini, M., Zanzi, C., Rotondo, F., Lorenzini, A., Marchionni, S., Paolini, M., 2019
How quickly do patients see results
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial
Choose from 2mg and 5mg peptide vials, peptide stacks and blends for potential synergy, 15ml and 30ml nasal sprays, or pre-mixed peptide pens